Browsing Det matematisk-naturvitenskapelige fakultet by Author "Waage, Anders"

Now showing items 1-3 of 3

  • BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis 
    Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola; Hovig, Eivind; Nakken, Sigve; Vodak, Daniel; Meza-Zepeda, Leonardo A.; Sandvik, Arne Kristian; Wader, Karin Fahl; Misund, Kristine; Sundan, Anders; Aarset, Harald; Waage, Anders (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF ...
  • Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence 
    Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco M.; Rustad, Even Holth; Sanders, Mathijs A.; Rye, Morten Beck; Sponaas, Anne-Marit; van der Holt, Bronno; Zweegman, Sonja; Hovig, Eivind; Meza, Leonardo Zepeda; Sundan, Anders; Myklebost, Ola; Sonneveld, Pieter; Waage, Anders (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Abstract We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study before and after treatment. A change in clonal ...
  • Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines 
    Giliberto, Mariaserena; Miranda Santana, Leonardo; Holien, Toril; Misund, Kristine; Nakken, Sigve; Vodak, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Coward, Eivind; Waage, Anders; Tasken, Kjetil; Skånland, Sigrid S (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Introduction Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet ...